BioCentury | Apr 14, 2021
Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

Immune medicines company Repertoire Immune Medicines Inc. raised $189 million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Oct 2, 2019
Financial News

Three new IPO filings broaden fall queue

A trio of biotechs filed for NASDAQ listings late Monday, with Phathom, 4D Molecular Therapeutics and Cabaletta each proposing to raise up to $100 million. A fourth, Vir, set terms for an IPO that could...
BioCentury | Sep 13, 2019
Tools & Techniques

Enzymes aim to beat chemistry by creating longer, speedier, cleaner DNA strands

The first new chemistry for DNA writing in 30 years is gathering steam, with enzymatic synthesis startups developing platforms to generate longer, purer DNA strands in record time. While the new players aim to outperform...
BioCentury | Jun 14, 2017
Distillery Therapeutics

Hematology

...disease caused by loss-of-function SLC40A1 mutations. In mouse erythroleukemia cells deficient in the iron transporter SLC11A2...
...hinokitiol and its analogs (see “Pumping Iron.” BioCentury Innovations (June 8, 2017)). TARGET/MARKER/PATHWAY: Solute carrier family 11 proton-coupled divalent metal ion transporter member 2 (SLC11A2; DMT1...
...of Illinois, Champaign, Ill. email: mdburke@illinois.edu Michael Leviten Brigham and Women's Hospital University of Illinois at Urbana-Champaign Solute carrier family 11 proton-coupled divalent metal ion transporter member 2 (SLC11A2) (DMT1) Solute...
BioCentury | Jun 8, 2017
Targets & Mechanisms

Pumping iron

...in mammalian cells lacking SLC11A2, SLC40A1 or mitoferrin, which mediate three different iron-dependent physiological processes. SLC11A2...
...across the relevant membrane, dissipating the built-up gradient. Mitoferrin (MTFN; MTFN1; SLC25A37); SLC11A2 (DMT1) - Solute carrier family 11 proton-coupled divalent metal ion transporter member 2...
...NASDAQ:RMTI), Wixom, Mich. University of Illinois, Champaign, Ill. Targets EPO - Erythropoietin SLC11A2 (DMT1) - Solute carrier family 11 proton-coupled divalent metal ion transporter member 2...
BioCentury | Jan 20, 2017
Clinical News

DMT210: Ph II DMT210-003 started

Dermata began the double-blind, vehicle-controlled, U.S. Phase II DMT210-003 trial to evaluate DMT210 5% topical gel twice daily for 12 weeks in about 104 patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see...
BioCentury | Dec 9, 2016
Clinical News

DMT210: Ph II DMT210-02 started

Dermata began the double-blind, vehicle-controlled, U.S. Phase II DMT210-002 trial to evaluate twice-daily topical DMT210 gel for 28 days in 25 patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27,...
BioCentury | Oct 3, 2016
Clinical News

SIG990: Phase I data

Top-line data from an open-label, U.S. Phase I trial in patients with acne rosacea showed that twice-daily topical DMT210 for 28 days was well tolerated and reduced erythema and lesion counts. This year, Dermata plans...
BioCentury | May 23, 2016
Clinical News

SIG990: Phase I started

Dermata began an open-label, U.S. Phase I trial to evaluate twice-daily topical DMT210 for 28 days in 10 patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27, 2015). Dermata Therapeutics...
Items per page:
1 - 10 of 18